Priapizm (Polish Wikipedia)

Analysis of information sources in references of the Wikipedia article "Priapizm" in Polish language version.

refsWebsite

Global rank Polish rank

11nih.gov

4^th place

7^th place

7worldcat.org

5^th place

2^nd place

5doi.org

2^nd place

6^th place

1web.archive.org

1^st place

1standardy.pl

low place

doi.org

dx.doi.org

A.W.A.W. Schneider A.W.A.W. i inni, Der papaverin-induzierte Priapisimus: Erfahrungen mit einem neuen urologischen Notfall, „Deutsche Medizinische Wochenschrift”, 114 (06), 1989, s. 214–217, DOI: 10.1055/s-2008-1066578, ISSN 0012-0472, PMID: 2917481 (niem.).
Otto I.O.I. Linet Otto I.O.I., Francis G.F.G. Ogrinc Francis G.F.G., Efficacy and safety of intracavernosal alprostadil in men with erectile dysfunction. The Alprostadil Study Group, „The New England Journal of Medicine”, 334 (14), 1996, s. 873–877, DOI: 10.1056/NEJM199604043341401, ISSN 0028-4793, PMID: 8596569 .
RicardoR. Munarriz RicardoR. i inni, Cocaine and ephedrine-induced priapism: case reports and investigation of potential adrenergic mechanisms, „Urology”, 62 (1), 2003, s. 187–192, DOI: 10.1016/S0090-4295(03)00245-0, ISSN 1527-9995, PMID: 12837464 .

doi.org

A.L. Burnett, T.J. Bivalacqua, H.C. Champion, B. Musicki. Long-term oral phosphodiesterase 5 inhibitor therapy alleviates recurrent priapism. „Urology”. 67 (5), s. 1043–1048, May 2006. DOI: 10.1016/j.urology.2005.11.045. PMID: 16698365.
A.L. Burnett, T.J. Bivalacqua, H.C. Champion, B. Musicki. Feasibility of the use of phosphodiesterase type 5 inhibitors in a pharmacologic prevention program for recurrent priapism. „J Sex Med”. 3 (6), s. 1077–1084, Nov 2006. DOI: 10.1111/j.1743-6109.2006.00333.x. PMID: 17100941.

nih.gov

ncbi.nlm.nih.gov

A.A. Fouda A.A. i inni, Priapism: an avoidable complication of pharmacologically induced erection, „The Journal of Urology”, 142 (4), 1989, s. 995–997, ISSN 0022-5347, PMID: 2795759 .
A.W.A.W. Schneider A.W.A.W. i inni, Der papaverin-induzierte Priapisimus: Erfahrungen mit einem neuen urologischen Notfall, „Deutsche Medizinische Wochenschrift”, 114 (06), 1989, s. 214–217, DOI: 10.1055/s-2008-1066578, ISSN 0012-0472, PMID: 2917481 (niem.).
Chris G.Ch.G. McMahon Chris G.Ch.G., Erectile dysfunction, „The Medical Journal of Australia”, 173 (9), 2000, s. 492–497, ISSN 0025-729X, PMID: 11149308 .
Otto I.O.I. Linet Otto I.O.I., Francis G.F.G. Ogrinc Francis G.F.G., Efficacy and safety of intracavernosal alprostadil in men with erectile dysfunction. The Alprostadil Study Group, „The New England Journal of Medicine”, 334 (14), 1996, s. 873–877, DOI: 10.1056/NEJM199604043341401, ISSN 0028-4793, PMID: 8596569 .
C. Van der Horst, H. Stuebinger, C. Seif, D. Melchior i inni. Priapism – etiology, pathophysiology and management. „Int Braz J Urol”. 29 (5). s. 391–400. PMID: 15745583.
J.E.J.E. Baños J.E.J.E., F.F. Bosch F.F., M.M. Farré M.M., Drug-induced priapism. Its aetiology, incidence and treatment, „Medical Toxicology and Adverse Drug Experience”, 4 (1), 1989, s. 46–58, ISSN 0113-5244, PMID: 2651850 .
M.M. Haria M.M., A.A. Fitton A.A., D.D. McTavish D.D., Trazodone. A review of its pharmacology, therapeutic use in depression and therapeutic potential in other disorders, „Drugs & Aging”, 4 (4), 1994, s. 331–355, ISSN 1170-229X, PMID: 8019056 .
RicardoR. Munarriz RicardoR. i inni, Cocaine and ephedrine-induced priapism: case reports and investigation of potential adrenergic mechanisms, „Urology”, 62 (1), 2003, s. 187–192, DOI: 10.1016/S0090-4295(03)00245-0, ISSN 1527-9995, PMID: 12837464 .
A.L. Burnett, T.J. Bivalacqua, H.C. Champion, B. Musicki. Long-term oral phosphodiesterase 5 inhibitor therapy alleviates recurrent priapism. „Urology”. 67 (5), s. 1043–1048, May 2006. DOI: 10.1016/j.urology.2005.11.045. PMID: 16698365.
A.L. Burnett, T.J. Bivalacqua, H.C. Champion, B. Musicki. Feasibility of the use of phosphodiesterase type 5 inhibitors in a pharmacologic prevention program for recurrent priapism. „J Sex Med”. 3 (6), s. 1077–1084, Nov 2006. DOI: 10.1111/j.1743-6109.2006.00333.x. PMID: 17100941.
J. Pohl, B. Pott, G. Kleinhans. Priapism: a three-phase concept of management according to aetiology and prognosis. „Br J Urol”. 58 (2), s. 113–118, Apr 1986. PMID: 3516294.

standardy.pl

Priapizm -współczesne poglądy Standardy Medyczne, 2002, Nr 5, Tom 3.

web.archive.org

Kuczyński W, Rzewuska M, Luks M.: Wpływ leków przeciwpsychotycznych na funkcje seksualne.Seksuologia Polska 2003, 1, 1, 23–29.

worldcat.org

A.A. Fouda A.A. i inni, Priapism: an avoidable complication of pharmacologically induced erection, „The Journal of Urology”, 142 (4), 1989, s. 995–997, ISSN 0022-5347, PMID: 2795759 .
A.W.A.W. Schneider A.W.A.W. i inni, Der papaverin-induzierte Priapisimus: Erfahrungen mit einem neuen urologischen Notfall, „Deutsche Medizinische Wochenschrift”, 114 (06), 1989, s. 214–217, DOI: 10.1055/s-2008-1066578, ISSN 0012-0472, PMID: 2917481 (niem.).
Chris G.Ch.G. McMahon Chris G.Ch.G., Erectile dysfunction, „The Medical Journal of Australia”, 173 (9), 2000, s. 492–497, ISSN 0025-729X, PMID: 11149308 .
Otto I.O.I. Linet Otto I.O.I., Francis G.F.G. Ogrinc Francis G.F.G., Efficacy and safety of intracavernosal alprostadil in men with erectile dysfunction. The Alprostadil Study Group, „The New England Journal of Medicine”, 334 (14), 1996, s. 873–877, DOI: 10.1056/NEJM199604043341401, ISSN 0028-4793, PMID: 8596569 .
J.E.J.E. Baños J.E.J.E., F.F. Bosch F.F., M.M. Farré M.M., Drug-induced priapism. Its aetiology, incidence and treatment, „Medical Toxicology and Adverse Drug Experience”, 4 (1), 1989, s. 46–58, ISSN 0113-5244, PMID: 2651850 .
M.M. Haria M.M., A.A. Fitton A.A., D.D. McTavish D.D., Trazodone. A review of its pharmacology, therapeutic use in depression and therapeutic potential in other disorders, „Drugs & Aging”, 4 (4), 1994, s. 331–355, ISSN 1170-229X, PMID: 8019056 .
RicardoR. Munarriz RicardoR. i inni, Cocaine and ephedrine-induced priapism: case reports and investigation of potential adrenergic mechanisms, „Urology”, 62 (1), 2003, s. 187–192, DOI: 10.1016/S0090-4295(03)00245-0, ISSN 1527-9995, PMID: 12837464 .